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Background:  Vorapaxar inhibits protease-activated receptor 1 expressed on platelets and vascular endothelium and reduces ischemic events and 
revascularization. We investigated whether the reduction in peripheral revascularization with vorapaxar was consistent in patients with polyvascular 
disease.
methods: TRA2°P-TIMI 50 was a randomized, placebo controlled trial of vorapaxar in 26,449 stable pts with prior MI, PAD, and CVD. We evaluated 
the rates of subsequent peripheral (limb) revascularization and bleeding with vorapaxar compared with placebo stratified by the number of diseased 
vascular beds. 
results: Rates of ischemic events (CV death/MI/Stroke) at 3 years increased with the number of symptomatic vascular beds (7.8% one, 14.7% 
two, 21.7% three). The rate of peripheral revascularization increased with the number of diseased vascular beds (Fig A) and was reduced consistently 
by vorapaxar (overall HR 0.79, p<0.001, p-interaction = 0.17). Vorapaxar also decreased subsequent limb revascularizations in pts who qualified 
with MI or stroke and were not known to have PAD at the time of randomization (HR 0.60, 95% CI 0.39-0.91, p=0.017). Bleeding increased with 
diseased vascular beds (Fig B) and was consistently increased with vorapaxar (p-interaction = 0.49, Fig B)
conclusions: The rate of peripheral revascularization and bleeding is associated with the number of diseased vascular beds. Vorapaxar reduces 
peripheral revascularization regardless of known PAD or number of diseased vascular beds.
 
